Synergistic effects of polymer adsorbents on the performance of bilirubin hemoperfusion. Issue 17 (22nd November 2017)

• Record Type: Journal Article
• Authors: Ma, Kai-wang; Yao, Da-hu; Li, Yang; Li, Guang-da; Cherukury, Hemanth; Jing, Ai-hua; Liang, Gao-feng
• Is Part Of: Journal of biomaterials science. Volume 28:Issue 17(2017)
• Page Start: 2053
• Page End: 2065
• Publication Date: 2017-11-22
• Subjects: Bilirubin -- adsorption -- polymer -- synergistic effect -- neonatal hyperbilirubinemia; Polymers -- Biocompatibility -- Periodicals; Biomedical materials -- Periodicals; 572.33
• DOI: 10.1080/09205063.2017.1370300
• Languages: English
• ISSNs: 0920-5063

Abstract

Abstract: Neonatal hyperbilirubinemia (jaundice) is a common disease with high incidence. Currently, the clinical inefficiency of adult bilirubin hemoperfusion medical adsorbent is a major technical barrier for the application of hemoperfusion treatment to rescue the severe neonatal jaundice. Based on the well-known principle of synergistic effects, a series of customized bilirubin polymeric compounds, comprised of one or more of the following components (glycidyl methacrylate, sodium acrylate, methacrylic acid isooctyl, hexamethylene diamine, albumin), were designed and fabricated based on molecular design. Their adsorption performances upon bilirubin were investigated and compared under the same conditions, and the compound with the highest adsorption performance was then subject to preliliminary safety assessments and compared with a commercial one (BS330). The results showed that positive synergistic effects appeared on the adsorption performance to adsorb bilirubin based on this study, and the one comprised of glycidyl methacrylate+sodium acrylate+methacrylic acid isoocty+hexamethylene diamine+albumin possesses the highest adsorption performance as well as outome clinical acceptable medical safety assessments, and its adsorption efficiency was up to 46% while the commerical one's was about 26% under the same conditions. This study sheds a new light on how to design and develop hemoperfusion bilirubin adsorbents with good overall clinical performance, as well as providing a novel idea and experimental referrences for future related topics.